The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4000 participants.

Also called NCT02575092

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 4,000 participants (enrolled count) (from the registry)
Sponsor
Fuling Central Hospital of Chongqing City (from the registry)
Registry
  • NCT NCT02575092
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02575092. Randomized; double masking; primary purpose treatment. Start 2015-11-01 (actual); primary completion 2019-02-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
Acronym
CONTRAST-CADT
Condition
Homocysteine
Condition
Coronary Disease
Condition
Angioplasty,Balloon,Coronary
Condition
Contrast Media
Condition
Nephropathy
Condition
Hypertension
Intervention (Drug)
Enalapril Maleate Tablets(as the program-based antihypertension)
Intervention (Drug)
Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)
Intervention (Drug)
Placebo
Lead sponsor
Fuling Central Hospital of Chongqing City (class: other)

Record details

Record id
cardio:ct-nct02575092
Content hash
b27eef4b6a7f608590c3b6d12441480deecfd2191c7aa7a2407245556cc1f0d5